Physician profile
Vikram Khetpal
NPI 1942281761
$8,915.13
in general payments reported to CMS, 2019-2025
43 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $730 · 2021: $1,908 · 2022: $1,249 · 2023: $1,268 · 2024: $1,034 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,290.53 | 2019-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Janssen Pharmaceuticals, INC | $832.23 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $784.22 | 2019-2025 | |
| Pfizer INC. | $735.58 | 2019-2025 | |
| Amgen INC. | $592.39 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $567.57 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $539.87 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $284.15 | 2019-2022 | |
| Cvrx, INC. | $278.94 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $276.31 | 2019-2023 | Gallant |
| Actelion Pharmaceuticals US, INC. | $263.21 | 2019-2025 | Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.08 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $241.43 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $240.78 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $228.06 | 2020-2025 | Nexletol |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Khetpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.